Víctor Moreno
Institut Català d'Ornitologia(ES)Bellvitge University Hospital(ES)Institut Català d'Oncologia(ES)Hospital Universitario Fundación Jiménez Díaz(ES)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, HER2/EGFR in Cancer Research, Monoclonal and Polyclonal Antibodies Research, Lung Cancer Treatments and Mutations, CAR-T cell therapy research
Most-Cited Works
- → PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma(2018)1,358 cited
- → HER kinase inhibition in patients with HER2- and HER3-mutant cancers(2018)769 cited
- → The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial(2013)552 cited
- → Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study(2019)550 cited
- → NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial(2019)473 cited
- → Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial